Advancements in Gastroenterology: A Weekly Review
Gastroenterologia
Advances in Gastroenterology and Hepatology
This week's episode covers recent advances in NAFLD treatment, Crohn's disease management strategies, and the therapeutic potential of fecal microbiota transplantation.
Accedi o Registrati per ascoltare questo episodio
Bibliografia
1. Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis.
Authors: Li S, Duan F, Li S, et al.
Journal: Annals of hepatology, 2024 Mar-Apr
PMID: 38579127
DOI: 10.1016/j.aohep.2023.101174
2. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Authors: Noor NM, Lee JC, Bond S, et al.
Journal: The lancet. Gastroenterology & hepatology, 2024 May
PMID: 38402895
DOI: 10.1016/S2468-1253(24)00034-7
3. Fecal microbiota transplantation: current challenges and future landscapes.
Authors: Yadegar A, Bar-Yoseph H, Monaghan TM, et al.
Journal: Clinical microbiology reviews, 2024 Jun 13
PMID: 38717124
DOI: 10.1128/cmr.00060-22
4. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Authors: Loomba R, Abdelmalek MF, Armstrong MJ, et al.
Journal: The lancet. Gastroenterology & hepatology, 2023 Jun
PMID: 36934740
DOI: 10.1016/S2468-1253(23)00068-7
5. Long-term safety of vedolizumab for inflammatory bowel disease.
Authors: Loftus EV Jr, Feagan BG, Panaccione R, et al.
Journal: Alimentary pharmacology & therapeutics, 2020 Oct
PMID: 32876349
DOI: 10.1111/apt.16060
6. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Authors: Feagan BG, Sandborn WJ, Gasink C, et al.
Journal: The New England journal of medicine, 2016 Nov 17
PMID: 27959607
DOI: 10.1056/NEJMoa1602773
7. Biomimetic materials for medical applications.
Authors: Zhang Y, Guo J, Luo Q, et al.
Journal: Chinese medical journal, 2026 May 20
PMID: 41906208
DOI: 10.1097/CM9.0000000000004036
8. Artificial intelligence and capsule endoscopy.
Authors: Casanova Rimer G, Urpí Ferreruela M, Bretto E, et al.
Journal: Revista espanola de enfermedades digestivas, 2026 May
PMID: 41848084
DOI: 10.17235/reed.2026.11191/2025
9. Understanding the gut microbiota and sarcopenia: a systematic review.
Authors: Liu C, Cheung WH, Li J, et al.
Journal: Journal of cachexia, sarcopenia and muscle, 2021 Dec
PMID: 34523250
DOI: 10.1002/jcsm.12784
10. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Authors: Loomba R, Abdelmalek MF, Armstrong MJ, et al.
Journal: The lancet. Gastroenterology & hepatology, 2023 Jun
PMID: 36934740
DOI: 10.1016/S2468-1253(23)00068-7
Authors: Li S, Duan F, Li S, et al.
Journal: Annals of hepatology, 2024 Mar-Apr
PMID: 38579127
DOI: 10.1016/j.aohep.2023.101174
2. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
Authors: Noor NM, Lee JC, Bond S, et al.
Journal: The lancet. Gastroenterology & hepatology, 2024 May
PMID: 38402895
DOI: 10.1016/S2468-1253(24)00034-7
3. Fecal microbiota transplantation: current challenges and future landscapes.
Authors: Yadegar A, Bar-Yoseph H, Monaghan TM, et al.
Journal: Clinical microbiology reviews, 2024 Jun 13
PMID: 38717124
DOI: 10.1128/cmr.00060-22
4. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Authors: Loomba R, Abdelmalek MF, Armstrong MJ, et al.
Journal: The lancet. Gastroenterology & hepatology, 2023 Jun
PMID: 36934740
DOI: 10.1016/S2468-1253(23)00068-7
5. Long-term safety of vedolizumab for inflammatory bowel disease.
Authors: Loftus EV Jr, Feagan BG, Panaccione R, et al.
Journal: Alimentary pharmacology & therapeutics, 2020 Oct
PMID: 32876349
DOI: 10.1111/apt.16060
6. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Authors: Feagan BG, Sandborn WJ, Gasink C, et al.
Journal: The New England journal of medicine, 2016 Nov 17
PMID: 27959607
DOI: 10.1056/NEJMoa1602773
7. Biomimetic materials for medical applications.
Authors: Zhang Y, Guo J, Luo Q, et al.
Journal: Chinese medical journal, 2026 May 20
PMID: 41906208
DOI: 10.1097/CM9.0000000000004036
8. Artificial intelligence and capsule endoscopy.
Authors: Casanova Rimer G, Urpí Ferreruela M, Bretto E, et al.
Journal: Revista espanola de enfermedades digestivas, 2026 May
PMID: 41848084
DOI: 10.17235/reed.2026.11191/2025
9. Understanding the gut microbiota and sarcopenia: a systematic review.
Authors: Liu C, Cheung WH, Li J, et al.
Journal: Journal of cachexia, sarcopenia and muscle, 2021 Dec
PMID: 34523250
DOI: 10.1002/jcsm.12784
10. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
Authors: Loomba R, Abdelmalek MF, Armstrong MJ, et al.
Journal: The lancet. Gastroenterology & hepatology, 2023 Jun
PMID: 36934740
DOI: 10.1016/S2468-1253(23)00068-7
